Log In
Print
BCIQ
Print
Print this Print this
 

antimiR-208 (miR-208)

  Manage Alerts
Collapse Summary General Information
Company miRagen Therapeutics Inc.
DescriptionModified short nucleic acid sequence targeting microRNA-208
Molecular Target MicroRNA-208 (miR-208)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: microRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationHeart failure
Indication DetailsTreat chronic heart failure (CHF)
Regulatory Designation
Partner Servier

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$352.0M

$45.0M

$307.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today